{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:41:12Z","timestamp":1767202872835,"version":"build-2238731810"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Behav. Neurosci."],"abstract":"<jats:p>\n                    Substance use disorders (SUDs) are associated with depression and anxiety, with the latter being one of the major factors in substance-seeking and relapse. Due to dose-dependent sedative side effects there is limited efficacy of baclofen treatment for SUDs. Here we suggest the use of a novel combination of opipramol and baclofen (O\/B) which is known to attenuate anxiety and depression, for the facilitation of recovery from SUDs. Since both opipramol and baclofen have a common downstream signal transduction, their individual doses could be reduced while still maintaining the benefits of the combination. We tested the O\/B combination in both animals and patients. Rats treated with O\/B showed significant attenuation in craving behavior and in relapse rate during withdrawal from cocaine. In a double-blind, placebo-controlled pilot study, conducted in a residential detoxification center, 14 males and 3 females, aged 28\u201360 years were assigned to a study (\n                    <jats:italic>n<\/jats:italic>\n                    = 6) and a placebo (\n                    <jats:italic>n<\/jats:italic>\n                    = 11) group (placebo group: 40 \u00b1 10.5 years; O\/B group 40 \u00b1 10.8 years). The participants completed scales measuring depression, anxiety and craving symptoms and provided saliva samples for stress hormone examination [cortisol and dehydroepiandrosterone-sulfate (DHEA-S)]. Participants with polysubstance use disorder (PsUD) treated with O\/B showed a reduction in cravings and depression and an increase in DHEA-S and in the DHEA-S\/cortisol ratio. Our findings indicate a beneficial effect of O\/B treatment. This study suggests a novel candidate for pharmacological treatment of patients with SUD and comorbid mood\/anxiety disorders that may facilitate their rehabilitation.\n                  <\/jats:p>","DOI":"10.3389\/fnbeh.2021.788708","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T05:03:21Z","timestamp":1640235801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder\u2014An Animal Model and a Human Study"],"prefix":"10.3389","volume":"15","author":[{"given":"Tzofnat","family":"Bareli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas Levi","family":"Ahdoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hila","family":"Ben Moshe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Royi","family":"Barnea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gal","family":"Warhaftig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Gispan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Maayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gal","family":"Yadid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000347055","article-title":"Efficacy and tolerability of baclofen in substance use disorders: a systematic review.","volume":"19","author":"Agabio","year":"2013","journal-title":"Eur. Addict. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD008581","DOI":"10.1002\/14651858.CD008581.pub2","article-title":"Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.","volume":"2018","author":"Agabio","year":"2018","journal-title":"Cochrane Database of Syst. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1365-2710.2001.00325.x","article-title":"Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.","volume":"26","author":"Ahmadi-Abhari","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e13014","DOI":"10.1111\/adb.13014","article-title":"Chronic opipramol treatment extinguishes cocaine craving through Rac1 in responders: a rat model study.","volume":"26","author":"Bareli","year":"2021","journal-title":"Addict. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/dar.12632","article-title":"Drug and alcohol treatment providers\u2019 views about the disease model of addiction and its impact on clinical practice: a systematic review.","volume":"37","author":"Barnett","year":"2018","journal-title":"Drug Alcohol Rev."},{"key":"B6","first-page":"333","article-title":"Structure\/activity studies at a baclofen-sensitive, bicuculline-insensitive GABA receptor.","volume":"29","author":"Bowery","year":"1981","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/283092a0","article-title":"(\u2013)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor.","volume":"283","author":"Bowery","year":"1980","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder\u2014a systematic meta-analysis.","volume":"138","author":"Bschor","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"B9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s0306-4530(01)00037-3","article-title":"Perturbations of plasma cortisol and DHEA-S following discontinuation of cocaine use in cocaine addicts.","volume":"27","author":"Buydens-Branchey","year":"2002","journal-title":"Psychoneuroendocrinology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s002130050937","article-title":"Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats.","volume":"143","author":"Campbell","year":"1999","journal-title":"Psychopharmacology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1080\/14656566.2020.1757649","article-title":"An update on the pharmacological management of pain in patients with multiple sclerosis.","volume":"21","author":"Chisari","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.15288\/jsad.2014.75.567","article-title":"Substance-induced depression and independent depression in proximal risk for suicidal behavior.","volume":"75","author":"Conner","year":"2014","journal-title":"J. Stud. Alcohol Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ana.410170202","article-title":"Antispasticity drugs: mechanisms of action.","volume":"17","author":"Davidoff","year":"1985","journal-title":"Ann. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fpsyt.2018.00708","article-title":"The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective.","volume":"9","author":"de Beaurepaire","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/sj.npp.1300088","article-title":"The GABAB receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats.","volume":"28","author":"Di Ciano","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1358\/dot.2005.41.11.904728","article-title":"Targeting the GABAB receptor for the treatment of depression and anxiety disorders.","volume":"29","author":"Felice","year":"2016","journal-title":"Receptors"},{"key":"B17","first-page":"199","article-title":"[3H]opipramol labels a novel binding site and sigma receptors in rat brain membranes.","volume":"39","author":"Ferris","year":"1991","journal-title":"Mol. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival.","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drugalcdep.2006.03.019","article-title":"Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence.","volume":"85","author":"Heinzerling","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugalcdep.2009.03.011","article-title":"Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals.","volume":"103","author":"Kahn","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/fbp.0000000000000209","article-title":"A role for sigma receptors in stimulant self-administration and addiction.","volume":"27","author":"Katz","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2042098620933741","DOI":"10.1177\/2042098620933741","article-title":"An overview of prevalence, determinants and health outcomes of polypharmacy.","volume":"11","author":"Khezrian","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1530-0277.2007.00342.x","article-title":"Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal.","volume":"31","author":"Knapp","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.jcp.0000194620.61868.35","article-title":"Sertraline treatment of co-occurring alcohol dependence and major depression.","volume":"26","author":"Kranzler","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.phrs.2009.06.010","article-title":"Muscle relaxant and neurotoxic activities of intrathecal baclofen in rats.","volume":"60","author":"Kuroiwa","year":"2009","journal-title":"Pharmacol. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.nec.2018.12.002","article-title":"Intrathecal baclofen infusion for the treatment of movement disorders.","volume":"30","author":"Lake","year":"2019","journal-title":"Neurosurg. Clin. N. Am."},{"key":"B28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/da.22122","article-title":"Prospective study of substance-induced and independent major depressive disorder among individuals with substance use disorders in a nationally representative sample.","volume":"30","author":"Magidson","year":"2013","journal-title":"Depress. Anxiety"},{"key":"B29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0893-133X(97)00113-9","article-title":"Neurobiological similarities in depression and drug dependence: a self-medication hypothesis.","volume":"18","author":"Markou","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.addbeh.2009.04.012","article-title":"Mono- and polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses.","volume":"34","author":"Martinotti","year":"2009","journal-title":"Addict. Behav."},{"key":"B31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0197-2456(02)00324-0","article-title":"Randomization in clinical trials: theory and practice.","volume":"24","author":"Matthews","year":"2003","journal-title":"Control Clin. Trials"},{"key":"B32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","article-title":"The GABA system in anxiety and depression and its therapeutic potential.","volume":"62","author":"M\u00f6hler","year":"2012","journal-title":"Neuropharmacology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00004714-200102000-00011","article-title":"Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group.","volume":"21","author":"M\u00f6ller","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","article-title":"Role of sigma-1 receptors in neurodegenerative diseases.","volume":"127","author":"Nguyen","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","article-title":"Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.","volume":"291","author":"Nunes","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/adb.12241","article-title":"Effect of dehydroepiandrosterone add-on therapy on mood, decision making and subsequent relapse of polydrug users.","volume":"21","author":"Ohana","year":"2016","journal-title":"Addict. Biol."},{"key":"B37","first-page":"170","author":"Paxinos","year":"2007","journal-title":"The Rat Brain in Stereotaxic Coordinates"},{"key":"B38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.biopsych.2004.07.016","article-title":"Antidepressant treatment of co-occurring depression and alcohol dependence.","volume":"56","author":"Pettinati","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1176\/appi.ajp.2012.12010112","article-title":"Current status of co-occurring mood and substance use disorders: a new therapeutic target.","volume":"170","author":"Pettinati","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1517\/17460441.2014.956076","article-title":"Targeting GABAB receptors for anti-abuse drug discovery.","volume":"9","author":"Phillips","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp053113","article-title":"Mood disorders and substance use disorder: a complex comorbidity.","volume":"3","author":"Quello","year":"2005","journal-title":"Sci. Pract. Perspect."},{"key":"B43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fpsyt.2019.00238","article-title":"Baclofen but not diazepam alleviates alcohol-seeking behavior and hypothalamic\u2013pituitary\u2013adrenal axis dysfunction in stressed withdrawn mice.","volume":"10","author":"Rabat","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s002130050293","article-title":"Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure.","volume":"131","author":"Roberts","year":"1997","journal-title":"Psychopharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0893-133x(96)00002-4","article-title":"Baclofen attenuates the reinforcing effects of cocaine in rats.","volume":"15","author":"Roberts","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"B46","first-page":"195","article-title":"The GABA(B) agonist baclofen modifies cocaine self-administration in rats.","volume":"9","author":"Shoaib","year":"1998","journal-title":"Behav. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1037\/1064-1297.12.2.126","article-title":"Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study.","volume":"12","author":"Shoptaw","year":"2004","journal-title":"Exp Clin Psychopharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.biopsych.2013.01.032","article-title":"Stress as a common risk factor for obesity and addiction.","volume":"73","author":"Sinha","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tips.2016.01.003","article-title":"The Sigma-1 receptor as a pluripotent modulator in living systems.","volume":"37","author":"Su","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2183\/pjab.94.026","article-title":"Diversity of structure and function of GABAB receptors: a complexity of GABAB-mediated signaling.","volume":"94","author":"Terunuma","year":"2018","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.20882\/adicciones.868","article-title":"Dual diagnosis in Depression: treatment recommendations.","volume":"30","author":"Tirado-Mu\u00f1oz","year":"2018","journal-title":"Adicciones"},{"key":"B52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.31887\/DCNS.2015.17.2\/btolliver","article-title":"Assessment and treatment of mood disorders in the context of substance abuse.","volume":"17","author":"Tolliver","year":"2015","journal-title":"Dialog. Clin. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/syn.20984","article-title":"Insights into the Sigma-1 receptor chaperone\u2019s cellular functions: a microarray report.","volume":"66","author":"Tsai","year":"2012","journal-title":"Synapse"},{"key":"B54","doi-asserted-by":"publisher","first-page":"105244","DOI":"10.1016\/j.nbd.2020.105244","article-title":"Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures.","volume":"150","author":"Vavers","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0924-977x(00)00074-2","article-title":"Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial.","volume":"10","author":"Volz","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B56","first-page":"1","article-title":"Addressing co-occurring mood and substance use disorders","author":"Westermeyer","year":"2003","journal-title":"Integrated Treatment for Mood and Substance Use Disorders"},{"key":"B57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/PEC.0000000000001090","article-title":"Baclofen pumps: uses and complications.","volume":"33","author":"Woolf","year":"2017","journal-title":"Pediatr. Emerg. Care"},{"key":"B58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fnmol.2012.00081","article-title":"Modulation of mood States as a major factor in relapse to substance use.","volume":"5","author":"Yadid","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fphar.2019.00528","article-title":"The roles of intracellular chaperone proteins, sigma receptors, in Parkinson\u2019s disease (PD) and Major Depressive Disorder (MDD).","volume":"10","author":"Yang","year":"2019","journal-title":"Front. Pharmacol."}],"updated-by":[{"DOI":"10.3389\/fnbeh.2022.952004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000}}],"container-title":["Frontiers in Behavioral Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2021.788708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T03:59:22Z","timestamp":1655092762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2021.788708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":59,"alternative-id":["10.3389\/fnbeh.2021.788708"],"URL":"https:\/\/doi.org\/10.3389\/fnbeh.2021.788708","relation":{},"ISSN":["1662-5153"],"issn-type":[{"value":"1662-5153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"788708"}}